Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
GRAIL, Inc. stock logo
GRAL
GRAIL
$32.17
+2.4%
$39.52
$12.33
$63.99
$1.16B3.261.36 million shs885,448 shs
LifeMD, Inc. stock logo
LFMD
LifeMD
$6.19
+1.3%
$11.04
$3.99
$15.84
$293.51M1.721.68 million shs2.72 million shs
Omada Health, Inc. stock logo
OMDA
Omada Health
$21.53
+5.9%
$18.12
$14.14
$28.40
$1.24BN/A696,630 shs284,450 shs
The Pennant Group, Inc. stock logo
PNTG
The Pennant Group
$25.16
+0.6%
$25.56
$21.18
$37.13
$869.53M1.48249,337 shs325,524 shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
GRAIL, Inc. stock logo
GRAL
GRAIL
-4.21%-6.49%-10.71%-16.12%+87.14%
LifeMD, Inc. stock logo
LFMD
LifeMD
-6.14%-10.54%-42.09%-43.27%+14.85%
Omada Health, Inc. stock logo
OMDA
Omada Health
-2.77%+5.39%+15.64%+2,032,999,900.00%+2,032,999,900.00%
The Pennant Group, Inc. stock logo
PNTG
The Pennant Group
-0.44%-6.72%+6.70%-12.68%-21.24%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
GRAIL, Inc. stock logo
GRAL
GRAIL
1.0802 of 5 stars
1.14.00.00.01.70.81.3
LifeMD, Inc. stock logo
LFMD
LifeMD
2.5912 of 5 stars
3.52.00.00.02.81.70.6
Omada Health, Inc. stock logo
OMDA
Omada Health
N/AN/AN/AN/AN/AN/AN/AN/A
The Pennant Group, Inc. stock logo
PNTG
The Pennant Group
3.6528 of 5 stars
3.35.00.00.01.42.51.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
GRAIL, Inc. stock logo
GRAL
GRAIL
2.25
Hold$31.50-2.08% Downside
LifeMD, Inc. stock logo
LFMD
LifeMD
3.00
Buy$12.86107.71% Upside
Omada Health, Inc. stock logo
OMDA
Omada Health
3.00
Buy$24.5714.13% Upside
The Pennant Group, Inc. stock logo
PNTG
The Pennant Group
2.60
Moderate Buy$33.4032.75% Upside

Current Analyst Ratings Breakdown

Latest LFMD, OMDA, GRAL, and PNTG Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/14/2025
The Pennant Group, Inc. stock logo
PNTG
The Pennant Group
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$31.00 ➝ $29.00
8/8/2025
Omada Health, Inc. stock logo
OMDA
Omada Health
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$27.00 ➝ $28.00
8/8/2025
Omada Health, Inc. stock logo
OMDA
Omada Health
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$21.00 ➝ $24.00
8/8/2025
Omada Health, Inc. stock logo
OMDA
Omada Health
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$23.00 ➝ $24.00
8/7/2025
LifeMD, Inc. stock logo
LFMD
LifeMD
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$14.00 ➝ $13.00
8/6/2025
LifeMD, Inc. stock logo
LFMD
LifeMD
Lake Street Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$18.00 ➝ $14.00
8/6/2025
LifeMD, Inc. stock logo
LFMD
LifeMD
KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$14.00 ➝ $12.00
7/16/2025
The Pennant Group, Inc. stock logo
PNTG
The Pennant Group
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetHold ➝ Hold$32.00 ➝ $28.00
7/14/2025
LifeMD, Inc. stock logo
LFMD
LifeMD
KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$12.00 ➝ $14.00
7/10/2025
LifeMD, Inc. stock logo
LFMD
LifeMD
Lake Street Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$12.00 ➝ $18.00
7/9/2025
Omada Health, Inc. stock logo
OMDA
Omada Health
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$21.00 ➝ $23.00
(Data available from 8/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
GRAIL, Inc. stock logo
GRAL
GRAIL
$134.29M8.64$28.22 per share1.14$64.21 per share0.50
LifeMD, Inc. stock logo
LFMD
LifeMD
$245.56M1.20N/AN/A$0.01 per share619.00
Omada Health, Inc. stock logo
OMDA
Omada Health
N/AN/AN/AN/AN/AN/A
The Pennant Group, Inc. stock logo
PNTG
The Pennant Group
$695.24M1.25$0.92 per share27.24$9.65 per share2.61
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
GRAIL, Inc. stock logo
GRAL
GRAIL
-$2.03B-$13.11N/AN/AN/A-329.86%-16.64%-14.02%N/A
LifeMD, Inc. stock logo
LFMD
LifeMD
-$18.88M-$0.21N/A51.58N/A-2.41%N/A-8.11%11/6/2025 (Estimated)
Omada Health, Inc. stock logo
OMDA
Omada Health
N/AN/A0.00N/AN/AN/AN/AN/A
The Pennant Group, Inc. stock logo
PNTG
The Pennant Group
$22.56M$0.7832.2628.592.073.36%9.85%4.04%11/5/2025 (Estimated)

Latest LFMD, OMDA, GRAL, and PNTG Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2025Q2 2025
GRAIL, Inc. stock logo
GRAL
GRAIL
-$3.14-$3.18-$0.04-$3.18$37.57 million$35.54 million
8/7/2025Q2 2025
Omada Health, Inc. stock logo
OMDA
Omada Health
-$0.15-$0.22-$0.07-$0.24$55.17 million$61.37 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
GRAIL, Inc. stock logo
GRAL
GRAIL
N/AN/AN/AN/AN/A
LifeMD, Inc. stock logo
LFMD
LifeMD
N/AN/AN/AN/AN/A
Omada Health, Inc. stock logo
OMDA
Omada Health
N/AN/AN/AN/AN/A
The Pennant Group, Inc. stock logo
PNTG
The Pennant Group
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
GRAIL, Inc. stock logo
GRAL
GRAIL
N/A
9.23
9.23
LifeMD, Inc. stock logo
LFMD
LifeMD
9.21
0.77
0.72
Omada Health, Inc. stock logo
OMDA
Omada Health
N/AN/AN/A
The Pennant Group, Inc. stock logo
PNTG
The Pennant Group
0.11
1.21
1.21

Institutional Ownership

CompanyInstitutional Ownership
GRAIL, Inc. stock logo
GRAL
GRAIL
N/A
LifeMD, Inc. stock logo
LFMD
LifeMD
35.52%
Omada Health, Inc. stock logo
OMDA
Omada Health
N/A
The Pennant Group, Inc. stock logo
PNTG
The Pennant Group
85.88%

Insider Ownership

CompanyInsider Ownership
GRAIL, Inc. stock logo
GRAL
GRAIL
N/A
LifeMD, Inc. stock logo
LFMD
LifeMD
18.40%
Omada Health, Inc. stock logo
OMDA
Omada Health
N/A
The Pennant Group, Inc. stock logo
PNTG
The Pennant Group
5.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
GRAIL, Inc. stock logo
GRAL
GRAIL
1,36036.05 millionN/AOptionable
LifeMD, Inc. stock logo
LFMD
LifeMD
23047.42 million38.69 millionOptionable
Omada Health, Inc. stock logo
OMDA
Omada Health
84957.58 millionN/AN/A
The Pennant Group, Inc. stock logo
PNTG
The Pennant Group
7,00034.56 million32.70 millionOptionable

Recent News About These Companies

Pennant Group (PNTG) Q2 Sales Up 30%

New MarketBeat Followers Over Time

Media Sentiment Over Time

GRAIL stock logo

GRAIL NASDAQ:GRAL

$32.17 +0.75 (+2.39%)
Closing price 04:00 PM Eastern
Extended Trading
$32.00 -0.17 (-0.53%)
As of 07:27 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

GRAIL, Inc. operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T. Huber, William H. Rastetter, Mostafa Ronaghi, and Richard D. Klausner on September 11, 2015 and is headquartered in Menlo Park, CA.

LifeMD stock logo

LifeMD NASDAQ:LFMD

$6.19 +0.08 (+1.31%)
Closing price 04:00 PM Eastern
Extended Trading
$6.23 +0.04 (+0.65%)
As of 07:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

LifeMD, Inc. operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies. It also provides LifeMD PC, a direct-to-consumer virtual primary care which includes 24/7 access to a provider for their primary care, urgent care, and chronic care needs; and offers virtual consultations and treatment, prescription medications, diagnostics and imaging, wellness coaching, and more. In addition, the company offers PDFSimpli, an online software as a service platform that allows users to create, edit, convert, sign, and share PDF documents; ResumeBuild which provides digital resume and cover letter services; SignSimpli, a digital signature platform; and LegalSimpli, a provider of legal forms for consumers and small businesses. It sells its products directly to consumers and through e-commerce platforms, as well as through third party partner channels. The company was formerly known as Conversion Labs, Inc. and changed its name to LifeMD, Inc. in February 2021. LifeMD, Inc. was incorporated in 1994 and is headquartered in New York, New York.

Omada Health stock logo

Omada Health NASDAQ:OMDA

$21.53 +1.20 (+5.90%)
As of 04:00 PM Eastern

Omada’s mission is to bend the curve. Our hope is that, one day, tomorrow’s epidemiologists will notice a bend in disease curves, wonder what might be happening, and conclude that part of that impact has been Omada. As part of that mission, we strive to inspire and enable people to make lasting health changes on their own terms. We deliver virtual care between doctor’s visits, providing an engaging, personalized, and integrated experience for our members that is designed to improve their health while delivering value for the employers, health plans, health systems, pharmacy benefit managers (“PBMs”), and other entities that cover the cost of our programs. As of 2022, more than 156 million Americans suffered from one or more chronic conditions, such as obesity, prediabetes, diabetes, hypertension, and musculoskeletal (“MSK”) conditions, and approximately 40% of U.S. adults suffered from two or more chronic conditions, based on data published in the Annals of Bioethics & Clinical Applications. Managing these conditions—and treating the acute problems they can lead to—creates significant costs for employers, health plans, PBMs, and other entities that pay for the cost of care. According to the American Diabetes Association (the “ADA”)’s report “Economic Costs of Diabetes in the U.S. in 2022,” chronic diseases were the leading driver of U.S. medical spend, with diabetes alone accounting for $1 out of every $7 spent. According to research published in Diabetes Care, in 2022, an employee with type 2 diabetes cost on average an additional $7,000 annually due to increased medical costs, absenteeism, and lost productivity. The direct medical cost of people living with diabetes increased by 35% from 2012 to 2022, despite stable diabetes prevalence. It doesn’t have to be that way. Many chronic conditions can be managed or prevented at a more reasonable cost. One reason these conditions are often not managed efficiently is that the U.S. healthcare system was built mainly on encounter-based reimbursement models that pay for specific services, primarily as issues arise. Between what can be short and infrequent office visits, patients are often left to manage their condition on their own. Many have a hard time sticking to care plans and health goals—losing weight, eating better, exercising more—and have few resources to turn to for ongoing questions, accountability, and support as they work to change their lifestyle. Behavior change is hard. Omada was created to make it easier. Our virtual care programs are rooted in evidence and combine relationship-based, human-led clinical care with purpose-built technology. We call this approach Compassionate Intelligence. We work to develop trust with each member and use technology to help us personalize their experience, enabling us to unlock results at scale. We sell our programs to customers that cover the cost for covered individuals. Our customers include employers that cover our programs for their employees and their dependents, health systems that cover our programs for patients, and any other entity that is financially responsible for costs of our programs for a population of covered lives. We also work closely with health plans and PBMs that either cover our programs for a portion of their members as our customers or act as channel partners reselling our programs to their own end customers. Our channel partners’ end customers typically consist of employers that cover our programs for their employees and their dependents. In general, our customers cover the cost of our programs for our members, except that members in our physical therapy program may incur copays, coinsurance, or deductibles, depending on plan design, much like in-person physical therapy. We launched our initial program in diabetes prevention and weight health in 2012, with the goal of showing that a virtual program could achieve the same clinical results as its in-person archetype. Through feedback from our customers, channel partners, members, and the market at large, we then recognized the need to create an integrated, multi-condition care platform to address multiple, commonly comorbid, chronic conditions. Today, we offer cardiometabolic programs for prediabetes, diabetes, and hypertension; a physical therapy program to address MSK conditions; additional support for members taking glucagon-like peptide-1 agonists (“GLP-1”) in our cardiometabolic programs (“GLP-1 Care Tracks”); and behavioral health support across all programs. Since our founding, our programs have had a meaningful, positive impact. As of March 31, 2025, we had more than 2,000 customers and over 679,000 total members enrolled in one or more programs, and we had supported over one million members since launch. We count a member as enrolled in a program to the extent their participation was billed at least once in the preceding 12 months. We believe our programs serve a clear need for our customers and channel partners as well as our members, which is reinforced by our strong customer satisfaction and member engagement rates. In 2024, our average customer satisfaction rate for the year was over 90% for each of program implementation and customer success. Our customer satisfaction rate is based on survey results from customers that launched a new program during the measured period, and we consider a customer to be satisfied if they rated our program implementation and ongoing customer success, as applicable, at a 5 or higher on a 7-point scale. We believe that our customer satisfaction rates are strong and reflect the value of our services to customers. In 2024, more than 55% of members still engaged with our cardiometabolic programs at least once per month after a year in the program, and over 50% still engaged monthly after two years. We consider members to be still engaged after one year or two years in the program if, during their twelfth or twenty-fourth month of program participation in a cardiometabolic program, they complete at least one interaction with us, such as logging in or interacting with the Omada mobile app, sending messages to Omada Care Team members, or recording metrics such as weight, blood pressure, or blood glucose values. On average, in 2024, members in a cardiometabolic program engaged more than 30 times per month throughout their first year. Based on our experience and feedback from customers, we believe these engagement rates to be positive and to demonstrate the attractiveness of our program to members. We are proud of our progress, and we are just getting started. We have experienced strong growth since our inception. Revenue increased by 38% from $122.8 million to $169.8 million for the years ended December 31, 2023 and 2024, respectively, and by 57% from $35.1 million to $55.0 million for the three months ended March 31, 2024 and 2025, respectively. We continue to generate revenue from recurring customers, as evidenced by our net dollar retention rate, which for customers who were contracted as of the beginning of the prior period, is calculated as total billings generated in a particular period divided by total billings generated in the prior period and was 110% and 128% for the years ended December 31, 2023 and 2024, respectively. We have a history of net losses, due in part to the significant investments we have made in the design and development of our programs and platform enhancements, and have not yet achieved profitability on an annual basis. Our principal executive offices are located San Francisco, California.

The Pennant Group stock logo

The Pennant Group NASDAQ:PNTG

$25.16 +0.16 (+0.64%)
Closing price 04:00 PM Eastern
Extended Trading
$25.14 -0.02 (-0.10%)
As of 07:02 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

The Pennant Group, Inc. provides healthcare services in the United States. It operates in two segments, Home Health and Hospice Services, and Senior Living Services. The company offers home health services, including clinical services, such as nursing, speech, occupational and physical therapy, medical social work, and home health aide services; and hospice services comprising clinical care, education, and counseling services for the physical, spiritual, and psychosocial needs of terminally ill patients and their families. It also provides senior living services, such as residential accommodations, activities, meals, housekeeping, and assistance in the activities of daily living to seniors who are independent or who require some support. The company operates home health, hospice, and home care agencies, as well as senior living communities throughout Arizona, California, Colorado, Idaho, Montana, Nevada, Oklahoma, Oregon, Texas, Utah, Washington, Wisconsin, and Wyoming. The Pennant Group, Inc. was incorporated in 2019 and is headquartered in Eagle, Idaho.